Bulent Cetin1, Mustafa Benekli1, Faysal Dane2, Cem Boruban3, Mahmut Gumus4, Berna Oksuzoglu5, Mehmet A Kaplan6, Gulnihal Tufan1, Alper Sevinc7, Ugur Coskun1, Suleyman Buyukberber1. 1. Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Gaziantep, Turkey. 2. Department of Medical Oncology, Marmara University Faculty of Medicine, Istanbul, Gaziantep, Turkey. 3. Department of Medical Oncology, Selcuk University Meram Faculty of Medicine, Konya, Gaziantep, Turkey. 4. Department of Medical Oncology, Dr. Lutfi Kirdar Kartal Training and Research Hospital, Istanbul, Gaziantep, Turkey. 5. Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Training and Research Hospital, Ankara, Gaziantep, Turkey. 6. Department of Medical Oncology, Dicle University Faculty of Medicine, Diyarbakir, Gaziantep, Turkey. 7. Department of Medical Oncology, Gaziantep University Faculty of Medicine, Gaziantep, Turkey.
Abstract
BACKGROUND: The efficacy and safety of the lapatinib and capecitabine combination remain elusive in elderly patients with metastatic breast cancer (MBC), who progress after trastuzumab-based therapy. PATIENTS AND METHODS: A total of 26 patients with HER2-positive MBC were included in this retrospective multicenter study. Median age was 69 years (range 65-82 years). All patients were treated with the combination of lapatinib (1,250 mg/day, continuously) and capecitabine (2,000 mg/m(2) on days 1-14 of a 21-day cycle). Data on demographics, clinical outcome, and toxicity were collected for descriptive analyses. RESULTS: The median follow-up was 10 months (range 2-31 months). An overall response rate of 33.4% was achieved, including 1 complete response (3.8%), and 8 partial responses (30.8%). Median progression-free survival was 7 months (95% confidence interval (CI) 5-8), and the median overall survival was 15 months (95% CI 11-19). Most common side effects were fatigue (53.8%), diarrhea (46%), vomiting (36.3%), hand-foot syndrome (34.5%), and anorexia (34.6%). Grade 3-4 toxicities were identified as hand-foot syndrome (3.8%), diarrhea (7.6%), and fatigue (11.5%). There were no symptomatic cardiac events. CONCLUSION: Lapatinib and capecitabine combination therapy was effective and well tolerated in elderly patients with MBC, who had progressive disease after trastuzumab-based therapy.
BACKGROUND: The efficacy and safety of the lapatinib and capecitabine combination remain elusive in elderly patients with metastatic breast cancer (MBC), who progress after trastuzumab-based therapy. PATIENTS AND METHODS: A total of 26 patients with HER2-positive MBC were included in this retrospective multicenter study. Median age was 69 years (range 65-82 years). All patients were treated with the combination of lapatinib (1,250 mg/day, continuously) and capecitabine (2,000 mg/m(2) on days 1-14 of a 21-day cycle). Data on demographics, clinical outcome, and toxicity were collected for descriptive analyses. RESULTS: The median follow-up was 10 months (range 2-31 months). An overall response rate of 33.4% was achieved, including 1 complete response (3.8%), and 8 partial responses (30.8%). Median progression-free survival was 7 months (95% confidence interval (CI) 5-8), and the median overall survival was 15 months (95% CI 11-19). Most common side effects were fatigue (53.8%), diarrhea (46%), vomiting (36.3%), hand-foot syndrome (34.5%), and anorexia (34.6%). Grade 3-4 toxicities were identified as hand-foot syndrome (3.8%), diarrhea (7.6%), and fatigue (11.5%). There were no symptomatic cardiac events. CONCLUSION:Lapatinib and capecitabine combination therapy was effective and well tolerated in elderly patients with MBC, who had progressive disease after trastuzumab-based therapy.
Entities:
Keywords:
Advanced breast cancer; Capecitabine; Elderly women; HER2; Lapatinib
Authors: Angelo Di Leo; Henry L Gomez; Zeba Aziz; Zanete Zvirbule; Jose Bines; Michael C Arbushites; Stephanie F Guerrera; Maria Koehler; Cristina Oliva; Steven H Stein; Lisa S Williams; Judy Dering; Richard S Finn; Michael F Press Journal: J Clin Oncol Date: 2008-10-27 Impact factor: 44.544
Authors: Henry L Gomez; Dinesh C Doval; Miguel A Chavez; Peter C-S Ang; Zeba Aziz; Shona Nag; Christina Ng; Sandra X Franco; Louis W C Chow; Michael C Arbushites; Michelle A Casey; Mark S Berger; Steven H Stein; George W Sledge Journal: J Clin Oncol Date: 2008-05-05 Impact factor: 44.544
Authors: Stephen Johnston; John Pippen; Xavier Pivot; Mikhail Lichinitser; Saeed Sadeghi; Veronique Dieras; Henry Leonidas Gomez; Gilles Romieu; Alexey Manikhas; M John Kennedy; Michael F Press; Julie Maltzman; Allison Florance; Lisa O'Rourke; Cristina Oliva; Steven Stein; Mark Pegram Journal: J Clin Oncol Date: 2009-09-28 Impact factor: 44.544
Authors: G Capri; J Chang; S-C Chen; P Conte; K Cwiertka; G Jerusalem; Z Jiang; S Johnston; B Kaufman; J Link; J Ro; J Schütte; C Oliva; R Parikh; A Preston; J Rosenlund; M Selzer; D Zembryki; S De Placido Journal: Ann Oncol Date: 2009-10-08 Impact factor: 32.976
Authors: David Cameron; Michelle Casey; Michael Press; Deborah Lindquist; Tadeusz Pienkowski; C Gilles Romieu; Stephen Chan; Agnieszka Jagiello-Gruszfeld; Bella Kaufman; John Crown; Arlene Chan; Mario Campone; Patrice Viens; Neville Davidson; Vera Gorbounova; Johannes Isaac Raats; Dimosthenis Skarlos; Beth Newstat; Debasish Roychowdhury; Paolo Paoletti; Cristina Oliva; Stephen Rubin; Steven Stein; Charles E Geyer Journal: Breast Cancer Res Treat Date: 2008-01-11 Impact factor: 4.872
Authors: Hans Wildiers; Ian Kunkler; Laura Biganzoli; Jacques Fracheboud; George Vlastos; Chantal Bernard-Marty; Arti Hurria; Martine Extermann; Véronique Girre; Etienne Brain; Riccardo A Audisio; Harry Bartelink; Mary Barton; Sharon H Giordano; Hyman Muss; Matti Aapro Journal: Lancet Oncol Date: 2007-12 Impact factor: 41.316
Authors: A Geneste; M N Duong; L Molina; L Conilh; S Beaumel; A Cleret; K Chettab; M Lachat; L P Jordheim; E L Matera; C Dumontet Journal: BMC Pharmacol Toxicol Date: 2020-08-14 Impact factor: 2.483